Virologica Sinica

, Volume 34, Issue 1, pp 106–110 | Cite as

A Vesicular Stomatitis Virus-Based Vaccine Carrying Zika Virus Capsid Protein Protects Mice from Viral Infection

  • Xiaodan Shi
  • Jingping Hu
  • Jing Guo
  • Chuanjian Wu
  • Sidong XiongEmail author
  • Chunsheng DongEmail author

Dear Editor,

Zika virus (ZIKV) is a mosquito-borne virus that belongs to the Flavivirus family along with dengue virus (DENV), yellow fever virus, West Nile virus, and Japanese encephalitis virus (Ming et al.2016). ZIKV is a single-stranded positive-sense RNA virus encoding three structural proteins, including nucleocapsid protein C, prM/M, envelope glycoprotein E, and seven non-structural proteins. Since 2015, over 70 countries and territories had reported continuing vector-borne transmission of ZIKV, making it a global public health issue. People infected with ZIKV normally have no or mild symptoms that include fever, rash, muscle pain, red eyes, headache, and conjunctivitis. However, a 2015 survey in Brazil found that the number of microcephaly cases dramatically increased, suggesting that ZIKV infection and newborn deformity were closely related (Heukelbach et al.2016). Additionally, ZIKV infection can cause other severe neurological disorders, such as Guillain–Barré syndrome...



We gratefully thank Dr. Feifei Yin in Hainan Medical University for providing ZIKV PRVABC59 and also like to thank Prof. Yi Shi in Institute of Microbiology, Chinese Academy of Sciences for providing the Zika E monoantibody. This work was supported by the National Natural Science Foundation of China (31470848, 31470880, 31670898, and 31870867), Open Research Fund Program of the State Key Laboratory of Virology of China (2017IOV003) and Jiangsu Provincial Innovative Research Team.

Author Contributions

XS, SX, and CD conceived and designed the research. XS, JH, JG, and CW carried out the experiments. SX and CD analyzed the data. SX and CD wrote the paper. All authors have read and approved the final manuscript.

Compliance with Ethical Standards

Conflict of interest

All the authors declare that they have no conflicts of interest.

Animal and Human Rights Statement

All animal experiments were performed in accordance with the guidelines of the Laboratory Animal Ethics Commission of Soochow University.

Supplementary material

12250_2019_83_MOESM1_ESM.pdf (180 kb)
Supplementary material 1 (PDF 181 kb)


  1. Abbink P, Larocca RA, Ra DLB, Bricault CA, Moseley ET, Boyd M, Kirilova M, Li Z, Ng’Ang’A D, Nanayakkara O (2016) Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys. Science 353:1129CrossRefPubMedPubMedCentralGoogle Scholar
  2. Agnandji ST, Huttner A, Zinser ME, Njuguna P, Dahlke C, Fernandes JF, Yerly S, Dayer JA, Kraehling V, Kasonta R et al (2016) Phase 1 trials of rVSV Ebola vaccine in Africa and Europe. N Engl J Med 374:1647–1660CrossRefPubMedGoogle Scholar
  3. Boigard H, Alimova A, Martin GR, Katz A, Gottlieb P, Galarza JM (2017) Zika virus-like particle (VLP) based vaccine. PLoS Negl Trop Dis 11:e0005608CrossRefPubMedPubMedCentralGoogle Scholar
  4. Cao-Lormeau VM, Blake A, Mons S, Lastere S, Roche C, Vanhomwegen J, Dub T, Baudouin L, Teissier A, Larre P et al (2016) Guillain–Barre Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet 387:1531–1539CrossRefPubMedPubMedCentralGoogle Scholar
  5. Cobleigh MA, Wei X, Robek MD (2013) A vesicular stomatitis virus-based therapeutic vaccine generates a functional CD8 T cell response to hepatitis B virus in transgenic mice. J Virol 87:2969–2973CrossRefPubMedPubMedCentralGoogle Scholar
  6. Gagnon SJ, Zeng W, Kurane I, Ennis FA (1996) Identification of two epitopes on the dengue 4 virus capsid protein recognized by a serotypespecific and a panel of serotype-cross-reactive human CD4+ cytotoxic T-lymphocyte clones. J Virol 70:141–147PubMedPubMedCentralGoogle Scholar
  7. Geisbert TW, Daddario-Dicaprio KM, Geisbert JB, Reed DS, Feldmann F, Grolla A, Stroher U, Fritz EA, Hensley LE, Jones SM, Feldmann H (2008) Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine 26:6894–6900CrossRefPubMedPubMedCentralGoogle Scholar
  8. Gil L, Izquierdo A, Lazo L, Valdes I, Ambala P, Ochola L, Marcos E, Suzarte E, Kariuki T, Guzman G, Guillen G, Hermida L (2014) Capsid protein: evidences about the partial protective role of neutralizing antibody-independent immunity against dengue in monkeys. Virology 456–457:70–76CrossRefPubMedGoogle Scholar
  9. Guzman MG, Harris E (2015) Dengue. Lancet 385:453–465CrossRefPubMedGoogle Scholar
  10. Heukelbach J, Alencar CH, Kelvin AA, de Oliveira WK, de Goes Pamplona, Cavalcanti L (2016) Zika virus outbreak in Brazil. J Infect Dev Ctries 10:116–120CrossRefPubMedGoogle Scholar
  11. Jones SM, Feldmann H, Stroher U, Geisbert JB, Fernando L, Grolla A, Klenk HD, Sullivan NJ, Volchkov VE, Fritz EA, Daddario KM, Hensley LE, Jahrling PB, Geisbert TW (2005) Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 11:786–790CrossRefPubMedGoogle Scholar
  12. Kahn JS, Roberts A, Weibel C, Buonocore L, Rose JK (2001) Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge. J Virol 75:11079–11087CrossRefPubMedPubMedCentralGoogle Scholar
  13. Kapadia SU, Rose JK, Lamirande E, Vogel L, Subbarao K, Roberts A (2005) Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine. Virology 340:174–182CrossRefPubMedGoogle Scholar
  14. Kawiecki AB, Christofferson RC (2016) Zika virus-induced antibody response enhances dengue virus serotype 2 replication in vitro. J Infect Dis 214:1357–1360CrossRefPubMedGoogle Scholar
  15. Larocca RA, Abbink P, Peron JP, Zanotto PM, Iampietro MJ, Badamchi-Zadeh A, Boyd M, Ng’ang’a D, Kirilova M, Nityanandam R et al (2016a) Vaccine protection against Zika virus from Brazil. Nature 536:474–478CrossRefPubMedPubMedCentralGoogle Scholar
  16. Larocca RA, Abbink P, Peron JPS, Zanotto PMDA, Iampietro MJ, Badamchi-Zadeh A, Boyd M, Ng’ang’a AD, Kirilova M, Nityanandam R (2016b) Vaccine protection against Zika virus from Brazil. Nature 536:474CrossRefPubMedPubMedCentralGoogle Scholar
  17. Lawson ND, Stillman EA, Whitt MA, Rose JK (1995) Recombinant vesicular stomatitis viruses from DNA. Proc Natl Acad Sci USA 92:4477–4481CrossRefPubMedGoogle Scholar
  18. Lazear HM, Diamond MS (2016) Zika virus: new clinical syndromes and its emergence in the Western Hemisphere. J Virol 90:4864–4875CrossRefPubMedPubMedCentralGoogle Scholar
  19. Lazo L, Hermida L, Zulueta A, Sanchez J, Lopez C, Silva R, Guillen G, Guzman MG (2007) A recombinant capsid protein from Dengue-2 induces protection in mice against homologous virus. Vaccine 25:1064–1070CrossRefPubMedGoogle Scholar
  20. Liu X, Qu L, Ye X, Yi C, Zheng X, Hao M, Su W, Yao Z, Chen P, Zhang S, Feng Y, Wang Q, Yan Q, Li P, Li H, Li F, Pan W, Niu X, Xu R, Feng L, Chen L (2018) Incorporation of NS1 and prM/M are important to confer effective protection of adenovirus-vectored Zika virus vaccine carrying E protein. NPJ Vaccines 3:29CrossRefPubMedPubMedCentralGoogle Scholar
  21. Ming GL, Tang H, Song H (2016) Advances in Zika virus research: stem cell models, challenges, and opportunities. Cell Stem Cell 19:690–702CrossRefPubMedPubMedCentralGoogle Scholar
  22. Pardi N, Hogan MJ, Pelc RS, Muramatsu H, Andersen H, DeMaso CR, Dowd KA, Sutherland LL, Scearce RM, Parks R et al (2017) Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature 543:248–251CrossRefPubMedPubMedCentralGoogle Scholar
  23. Reuter JD, Vivas-Gonzalez BE, Gomez D, Wilson JH, Brandsma JL, Greenstone HL, Rose JK, Roberts A (2002) Intranasal vaccination with a recombinant vesicular stomatitis virus expressing cottontail rabbit papillomavirus L1 protein provides complete protection against papillomavirus-induced disease. J Virol 76:8900–8909CrossRefPubMedPubMedCentralGoogle Scholar
  24. Richner JM, Himansu S, Dowd KA, Butler SL, Salazar V, Fox JM, Julander JG, Tang WW, Shresta S, Pierson TC, Ciaramella G, Diamond MS (2017) Modified mRNA vaccines protect against Zika virus infection. Cell 169:176CrossRefPubMedGoogle Scholar
  25. Roberts A, Kretzschmar E, Perkins AS, Forman J, Price R, Buonocore L, Kawaoka Y, Rose JK (1998) Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge. J Virol 72:4704–4711PubMedPubMedCentralGoogle Scholar
  26. Roberts A, Buonocore L, Price R, Forman J, Rose JK (1999) Attenuated vesicular stomatitis viruses as vaccine vectors. J Virol 73:3723–3732PubMedPubMedCentralGoogle Scholar
  27. Rose NF, Marx PA, Luckay A, Nixon DF, Moretto WJ, Donahoe SM, Montefiori D, Roberts A, Buonocore L, Rose JK (2001) An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 106:539–549CrossRefPubMedGoogle Scholar
  28. Teoh EP, Kukkaro P, Teo EW, Lim AP, Tan TT et al (2012) The structural basis for serotype specific neutralization of dengue virus by a human antibody. Sci Transl Med 4:139–183Google Scholar
  29. Xie X, Kum DB, Xia H, Luo H, Shan C, Zou J, Muruato AE, Medeiros DBA, Nunes BTD, Dallmeier K et al (2018) A single-dose live-attenuated Zika virus vaccine with controlled infection rounds that protects against vertical transmission. Cell Host Microbe 24(487–499):e485Google Scholar
  30. Xu K, Song Y, Dai L, Zhang Y, Lu X, Xie Y, Zhang H, Cheng T, Wang Q, Huang Q, Bi Y, Liu WJ, Liu W, Li X, Qin C, Shi Y, Yan J, Zhou D, Gao GF (2018) Recombinant chimpanzee adenovirus vaccine AdC7-M/E protects against Zika virus infection and testis damage. J Virol 92:e01722–17Google Scholar
  31. Zhao H, Fernandez E, Dowd KA, Speer SD, Platt DJ, Gorman MJ, Govero J, Nelson CA, Pierson TC, Diamond MS, Fremont DH (2016) Structural basis of Zika virus-specific antibody protection. Cell 166:1016–1027CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Wuhan Institute of Virology, CAS 2019

Authors and Affiliations

  1. 1.Jiangsu Key Laboratory of Infection and Immunity, The Institutes of Biology and Medical SciencesSoochow UniversitySuzhouChina

Personalised recommendations